Actelion Ltd (ALIOF) 99.5000 $ALIOF
3 Biotech Stocks Making Big Moves Last Week
Todd Campbell, The Motley Fool - Motley Fool - Mon May 05, 5:30PM CDT
Biotech investors have been taken on a roller coaster ride over the past few months as stratospheric gains in the fourth and first quarters have been realized to pay tax bills and rebalance to other industries. While Foolish investors should never...
Management Change at Actelion - Roland Haefeli to focus on senior advisory role - Andrew Weiss new Head of Investor Relations and Corporate Communications
Thomson Reuters ONE - Mon May 05, 12:01AM CDT
Actelion Pharmaceuticals Ltd / Management Change at Actelion - Roland Haefeli to focus on senior advisory role - Andrew Weiss new Head of Investor Relations and Corporate Communications . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
United Therapeutics Gains on Q1 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 01, 12:10PM CDT
United Therapeutics' (UTHR) first quarter earnings were significantly above expectations.
Global Mycosis Fungoides Global Clinical Trials Review 2014
M2 - Fri Apr 25, 8:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l6stqf/mycosis_fungoides) has announced the addition of the "Mycosis Fungoides Global Clinical Trials Review, H1, 2014" report to their offering. Mycosis Fungoides Global Clinical Trials Review, H1, 2014" provides data on the Mycosis Fungoides clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Mycosis Fungoides. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Mycosis Fungoides. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Mycosis Fungoides Therapeutics Clinical Trials - Merck & Co., Inc. - Takeda Pharmaceutical Company Limited - Shionogi & Co., Ltd. - Kirin Holdings Company, Limited - Eisai Co., Ltd. - Actelion Ltd - Janssen Global Services, LLC - Emergent BioSolutions Inc. - Echo Therapeutics, Inc. - Angimmune LLC Top Institutes / Government - National Cancer Institute - Fred Hutchinson Cancer Research Center - Northwestern University - University of Washington - Stanford University - The University of Texas M. D. Anderson Cancer Center - Memorial Sloan Kettering Cancer Center - Case Comprehensive Cancer Center - Barbara Ann Karmanos Cancer Institute - Wake Forest University For more information visit http://www.researchandmarkets.com/research/l6..._fungoides
Global Hypertension Drugs Market 2014-2018 with Actelion, AstraZeneca, Boehringer Ingelheim, Novartis, Pfizer, Sanofi Dominating
M2 - Thu Apr 24, 10:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/brq49m/global) has announced the addition of the "Global Hypertension Drugs Market 2014-2018" report to their offering. The Global Hypertension Drugs market is driven by several factors, of which an increase in aging population is one of the major drivers. There is a natural tendency for BP to rise with age due to the reduced elasticity of the arterial system. The promising hypertension drug pipeline is another major driver. The clinical pipeline for hypertension drugs is moderately strong with more emerging therapies. The Global Hypertension Drugs market is experiencing a shift toward combination products, using two or more combination treatments. A combination of hypertension therapy with separate agents or a fixed-dose combination pill lowers BP at a faster pace, helps in reaching the target BP, and decreases adverse effects. Additional benefits may include cost savings and better compliance. Moreover, antihypertensive agents from different classes may balance adverse reactions from each other. For instance, for hypertensive patients with diabetes, the recommended treatment includes diuretics, beta blockers, ACE inhibitors, ARBs, and/or CCBs. The Joint National Committee guidelines have recommended diuretics and ACE inhibitors for recurrent stroke prevention in patients with hypertension; beta blockers, ACE inhibitors, and aldosterone antagonists for hypertensive patients who are post myocardial infarction; and ACE inhibitors and ARBs for hypertensive patients with chronic kidney disease. Further, the report states that the increasing number of patent expirations is one of the main challenges. The patent expiries of major approved drugs will slow down the market growth, as the shift toward lower-priced drugs will lead to a drop in the market valuation for that drug, thereby reducing the overall market value. The Global Hypertension Drugs market can be categorized into eight segments: - Diuretics - ACE Inhibitors - ARBs - CCB - Beta Blockers - Alpha Blockers - Vasodilators - Renin Inhibitors. Key Vendors - Actelion Ltd. - AstraZeneca plc - Boehringer Ingelheim GmbH - Novartis AG - Pfizer Inc. - Sanofi SA Other Prominent Vendors - Bayer AG - Daiichi Sankyo Co. Ltd. - Forest Laboratories Inc. - Merck & Co. Inc. - Takeda Pharmaceutical Co. Ltd. - United Therapeutics Corp. - Valeant Pharmaceuticals International Inc. - XOMA LLC Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Rate of Incidence and Prevalence - Late Stage Pipeline Snapshot - Market Segmentation by Mechanism of Action - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/brq49m/global
Good News for Cleveland BioLabs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 4:20PM CDT
Cleveland BioLabs announced that it has achieved all objectives in a phase I trial on oncology candidate, CBL0102 (quinacrine).
Actelion Beats on Q1 Earnings and Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 10:00AM CDT
Actelion reported 1Q14 earnings of $1.64 per ADR, up 23.6% y/y, beating the Zacks Consensus Estimate of $1.12.
What Falling Estimates & Price Mean for Discovery Laboratories (DSCO) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 7:33AM CDT
A stock that investors may want to consider dropping is Discovery Laboratories Inc. (DSCO)
Actelion announces first quarter 2014 financial results
Thomson Reuters ONE - Thu Apr 17, 12:01AM CDT
Actelion Pharmaceuticals Ltd / Actelion announces first quarter 2014 financial results . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Actelion issues invitation to 2014 Annual General Meeting of Shareholders
Thomson Reuters ONE - Fri Apr 11, 12:01AM CDT
Actelion Pharmaceuticals Ltd / Actelion issues invitation to 2014 Annual General Meeting of Shareholders . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
The Medicines Co's Fibrocaps Under U.S. Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 5:08PM CDT
The FDA accepted the biologic license application (BLA) for The Medicines Co.'s dry powder formulation of Fibrocaps.
Weakness Seen in Kindred Biosciences (KIN): Stock Tumbles 9.0% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 7:48AM CDT
Kindred Biosciences, Inc. (KIN) saw a big move last session`,continuing the recent downtrend for KIN, as the stock is now down more than 28.0% in the past one-month time frame.
Good News for Keryx - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 5:20PM CDT
Keryx Biopharmaceuticals received good news when the European Medicines Agency (EMA) determined its Marketing Authorization Application (MAA) for lead candidate Zerenex as valid.
Myriad Genetics Jumps on Medicare Decision - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 1:50PM CDT
Shares of Myriad Genetics gained 11.47% on yesterday's close.
Myriad Genetics (MYGN) Worth Watching: Stock Rises 11.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 8:25AM CDT
Myriad Genetics was a big mover last session, with shares rising over 11% on the day.
What Falling Estimates & Price Mean for bluebird bio (BLUE) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 7:43AM CDT
One such stock that you may want to consider dropping is bluebird bio which witnessed negative earnings estimate revisions in current quarter and current year.
Bayer's Adempas Cleared in the EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 3:45PM CDT
Bayer's Adempas was approved in the EU for the CTEPH and PAH indications.
Ultragenyx (RARE) Jumps: Stock Rises 7.0% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 8:46AM CDT
Ultragenyx was a big mover last session, with shares rising 7% on the day.
Cara Therapeutics Inc. (CARA) Worth Watching: Stock Surges 12.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 7:57AM CDT
Cara Therapeutics Inc. was a big mover last session, as the company saw its shares rise nearly 13% on the day.
Keryx Biopharmaceuticals Inc. (KERX) Worth Watching: Stock Surges 17.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 7:44AM CDT
Keryx Biopharmaceuticals Inc. was a big mover last session, as the company saw its shares shoot up over 17% on the day.
3 Biotech Stocks Making Big Moves Last Week
Todd Campbell, The Motley Fool - Motley Fool - Mon May 05, 5:30PM CDT
Biotech investors have been taken on a roller coaster ride over the past few months as stratospheric gains in the fourth and first quarters have been realized to pay tax bills and rebalance to other industries. While Foolish investors should never...
Management Change at Actelion - Roland Haefeli to focus on senior advisory role - Andrew Weiss new Head of Investor Relations and Corporate Communications
Thomson Reuters ONE - Mon May 05, 12:01AM CDT
Actelion Pharmaceuticals Ltd / Management Change at Actelion - Roland Haefeli to focus on senior advisory role - Andrew Weiss new Head of Investor Relations and Corporate Communications . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
United Therapeutics Gains on Q1 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 01, 12:10PM CDT
United Therapeutics' (UTHR) first quarter earnings were significantly above expectations.
Global Mycosis Fungoides Global Clinical Trials Review 2014
M2 - Fri Apr 25, 8:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l6stqf/mycosis_fungoides) has announced the addition of the "Mycosis Fungoides Global Clinical Trials Review, H1, 2014" report to their offering. Mycosis Fungoides Global Clinical Trials Review, H1, 2014" provides data on the Mycosis Fungoides clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Mycosis Fungoides. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Mycosis Fungoides. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Mycosis Fungoides Therapeutics Clinical Trials - Merck & Co., Inc. - Takeda Pharmaceutical Company Limited - Shionogi & Co., Ltd. - Kirin Holdings Company, Limited - Eisai Co., Ltd. - Actelion Ltd - Janssen Global Services, LLC - Emergent BioSolutions Inc. - Echo Therapeutics, Inc. - Angimmune LLC Top Institutes / Government - National Cancer Institute - Fred Hutchinson Cancer Research Center - Northwestern University - University of Washington - Stanford University - The University of Texas M. D. Anderson Cancer Center - Memorial Sloan Kettering Cancer Center - Case Comprehensive Cancer Center - Barbara Ann Karmanos Cancer Institute - Wake Forest University For more information visit http://www.researchandmarkets.com/research/l6..._fungoides
Global Hypertension Drugs Market 2014-2018 with Actelion, AstraZeneca, Boehringer Ingelheim, Novartis, Pfizer, Sanofi Dominating
M2 - Thu Apr 24, 10:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/brq49m/global) has announced the addition of the "Global Hypertension Drugs Market 2014-2018" report to their offering. The Global Hypertension Drugs market is driven by several factors, of which an increase in aging population is one of the major drivers. There is a natural tendency for BP to rise with age due to the reduced elasticity of the arterial system. The promising hypertension drug pipeline is another major driver. The clinical pipeline for hypertension drugs is moderately strong with more emerging therapies. The Global Hypertension Drugs market is experiencing a shift toward combination products, using two or more combination treatments. A combination of hypertension therapy with separate agents or a fixed-dose combination pill lowers BP at a faster pace, helps in reaching the target BP, and decreases adverse effects. Additional benefits may include cost savings and better compliance. Moreover, antihypertensive agents from different classes may balance adverse reactions from each other. For instance, for hypertensive patients with diabetes, the recommended treatment includes diuretics, beta blockers, ACE inhibitors, ARBs, and/or CCBs. The Joint National Committee guidelines have recommended diuretics and ACE inhibitors for recurrent stroke prevention in patients with hypertension; beta blockers, ACE inhibitors, and aldosterone antagonists for hypertensive patients who are post myocardial infarction; and ACE inhibitors and ARBs for hypertensive patients with chronic kidney disease. Further, the report states that the increasing number of patent expirations is one of the main challenges. The patent expiries of major approved drugs will slow down the market growth, as the shift toward lower-priced drugs will lead to a drop in the market valuation for that drug, thereby reducing the overall market value. The Global Hypertension Drugs market can be categorized into eight segments: - Diuretics - ACE Inhibitors - ARBs - CCB - Beta Blockers - Alpha Blockers - Vasodilators - Renin Inhibitors. Key Vendors - Actelion Ltd. - AstraZeneca plc - Boehringer Ingelheim GmbH - Novartis AG - Pfizer Inc. - Sanofi SA Other Prominent Vendors - Bayer AG - Daiichi Sankyo Co. Ltd. - Forest Laboratories Inc. - Merck & Co. Inc. - Takeda Pharmaceutical Co. Ltd. - United Therapeutics Corp. - Valeant Pharmaceuticals International Inc. - XOMA LLC Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Rate of Incidence and Prevalence - Late Stage Pipeline Snapshot - Market Segmentation by Mechanism of Action - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/brq49m/global
Good News for Cleveland BioLabs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 4:20PM CDT
Cleveland BioLabs announced that it has achieved all objectives in a phase I trial on oncology candidate, CBL0102 (quinacrine).
Actelion Beats on Q1 Earnings and Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 10:00AM CDT
Actelion reported 1Q14 earnings of $1.64 per ADR, up 23.6% y/y, beating the Zacks Consensus Estimate of $1.12.
What Falling Estimates & Price Mean for Discovery Laboratories (DSCO) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 7:33AM CDT
A stock that investors may want to consider dropping is Discovery Laboratories Inc. (DSCO)
Actelion announces first quarter 2014 financial results
Thomson Reuters ONE - Thu Apr 17, 12:01AM CDT
Actelion Pharmaceuticals Ltd / Actelion announces first quarter 2014 financial results . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Actelion issues invitation to 2014 Annual General Meeting of Shareholders
Thomson Reuters ONE - Fri Apr 11, 12:01AM CDT
Actelion Pharmaceuticals Ltd / Actelion issues invitation to 2014 Annual General Meeting of Shareholders . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
The Medicines Co's Fibrocaps Under U.S. Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 5:08PM CDT
The FDA accepted the biologic license application (BLA) for The Medicines Co.'s dry powder formulation of Fibrocaps.
Weakness Seen in Kindred Biosciences (KIN): Stock Tumbles 9.0% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 7:48AM CDT
Kindred Biosciences, Inc. (KIN) saw a big move last session`,continuing the recent downtrend for KIN, as the stock is now down more than 28.0% in the past one-month time frame.
Good News for Keryx - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 5:20PM CDT
Keryx Biopharmaceuticals received good news when the European Medicines Agency (EMA) determined its Marketing Authorization Application (MAA) for lead candidate Zerenex as valid.
Myriad Genetics Jumps on Medicare Decision - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 1:50PM CDT
Shares of Myriad Genetics gained 11.47% on yesterday's close.
Myriad Genetics (MYGN) Worth Watching: Stock Rises 11.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 8:25AM CDT
Myriad Genetics was a big mover last session, with shares rising over 11% on the day.
What Falling Estimates & Price Mean for bluebird bio (BLUE) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 7:43AM CDT
One such stock that you may want to consider dropping is bluebird bio which witnessed negative earnings estimate revisions in current quarter and current year.
Bayer's Adempas Cleared in the EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 3:45PM CDT
Bayer's Adempas was approved in the EU for the CTEPH and PAH indications.
Ultragenyx (RARE) Jumps: Stock Rises 7.0% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 8:46AM CDT
Ultragenyx was a big mover last session, with shares rising 7% on the day.
Cara Therapeutics Inc. (CARA) Worth Watching: Stock Surges 12.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 7:57AM CDT
Cara Therapeutics Inc. was a big mover last session, as the company saw its shares rise nearly 13% on the day.
Keryx Biopharmaceuticals Inc. (KERX) Worth Watching: Stock Surges 17.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 7:44AM CDT
Keryx Biopharmaceuticals Inc. was a big mover last session, as the company saw its shares shoot up over 17% on the day.
